Back

Paediatric pulmonary arterial hypertension following congenital heart defect repair: enhanced risk stratification and outcomes in a national cohort

29 August 2022 (13:25 - 13:35)
Organised by:
Congress Presentation Part of: Pulmonary hypertension around the real world Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Andrew Constantine

Queen Elizabeth Hospital Birmingham, Birmingham (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Pulmonary arterial hypertension associated with congenital heart disease: real-world analysis of clinical characteristics, treatment patterns and outcomes from EXPOSURE
Doctor M. Escribano Subias (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Characterisation of pulmonary arterial hypertension patients with cardiovascular comorbidities treated with selexipag: real-world evidence from the EXPOSURE study
Professor S. Soderberg (Umea, SE)
Abstract Slides Video
Presentation thumbnail
Incident pulmonary hypertension in 13,448 cases investigated with repeat echocardiography: insight from the national echo database of australia (NEDA)
Professor S. Stewart (Fremantle, AU)
Abstract Slides Video
Presentation thumbnail
Concomitant initiation of combination therapy with macitentan and tadalafil in pulmonary arterial hypertension (PAH) patients with comorbidities: Real-world data from OPUS and OrPHeUS
Professor R. Channick (Los Angeles, US)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary hypertension around the real world

The Event

Event poster

ESC Congress 2022

29 August 2022 13:25 CET
You may be interested in
thumbnail
Congress Presentation
Epidemiology and management of patients with pulmonary arterial hypertension associated with congenital heart disease: data from the hellenic pulmonary hypertension registry (HOPE)
thumbnail
Congress Presentation
Pulmonary artery aneurysm in pulmonary arterial hypertension associated with congenital heart disease
thumbnail
Congress Presentation
Impact of triple vasodilator therapy on prognosis stratification of pulmonary arterial hypertension associated with congenital heart disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources